NASDAQ:CDNA - CareDx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$24.6687 +1.28 (+5.47 %)
(As of 01/16/2019 09:50 AM ET)
Previous Close$23.39
Today's Range$23.12 - $24.9950
52-Week Range$4.92 - $30.80
Volume68,254 shs
Average Volume791,061 shs
Market Capitalization$859.34 million
P/E Ratio-32.04
Dividend YieldN/A
Beta1.23
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300

Debt

Current Ratio2.65
Quick Ratio2.36

Price-To-Earnings

Sales & Book Value

Annual Sales$48.32 million
Price / Sales19.86
Price / Cash FlowN/A
Book Value($0.21) per share
Price / Book-117.47

Profitability

Net Income$-55,460,000.00
Net Margins-113.89%
Return on Assets-37.81%

Miscellaneous

Employees179
Market Cap$859.34 million
OptionableOptionable

CareDx (NASDAQ:CDNA) Frequently Asked Questions

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How were CareDx's earnings last quarter?

CareDx Inc (NASDAQ:CDNA) posted its earnings results on Thursday, November, 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.42. The company earned $21.18 million during the quarter, compared to analyst estimates of $18.47 million. CareDx had a negative net margin of 113.89% and a negative return on equity of 125.24%. View CareDx's Earnings History.

When is CareDx's next earnings date?

CareDx is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for CareDx.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $74-75 million, compared to the consensus revenue estimate of $69 million.

What price target have analysts set for CDNA?

4 brokerages have issued 1-year target prices for CareDx's shares. Their forecasts range from $27.00 to $42.00. On average, they anticipate CareDx's stock price to reach $34.75 in the next year. This suggests a possible upside of 40.9% from the stock's current price. View Analyst Price Targets for CareDx.

What is the consensus analysts' recommendation for CareDx?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

What are Wall Street analysts saying about CareDx stock?

Here are some recent quotes from research analysts about CareDx stock:
  • 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (1/8/2019)
  • 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $1,123M, which includes a discounted cash flow analysis based asset value for pre- and post-transplant tests, using a 15% discount rate and 2% terminal growth rate, and assuming 41.5M shares outstanding at the end of 2019." (12/21/2018)

Has CareDx been receiving favorable news coverage?

Media stories about CDNA stock have been trending positive on Wednesday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CareDx earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the next few days.

Who are some of CareDx's key competitors?

Who are CareDx's key executives?

CareDx's management team includes the folowing people:
  • Dr. Peter Maag, CEO & Director (Age 52)
  • Mr. Michael Bell, Chief Financial Officer (Age 50)
  • Dr. James P. Yee, Chief Medical Officer (Age 70)
  • Dr. Reginald Seeto, Pres & Chief Bus. Officer (Age 47)
  • Dr. Amy P. Abernethy, Chief Medical Officer, Chief Scientific Officer, Sr. VP of Oncology & Director (Age 50)

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $24.6687.

How big of a company is CareDx?

CareDx has a market capitalization of $859.34 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.

What is CareDx's official website?

The official website for CareDx is http://www.caredxinc.com.

How can I contact CareDx?

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]


MarketBeat Community Rating for CareDx (NASDAQ CDNA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel